These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 30363410)

  • 1. Subtle Esophageal Motility Alterations in Parkinsonian Syndromes: Synucleinopathies vs. Tauopathies.
    Claus I; Suttrup J; Muhle P; Suntrup-Krueger S; Siemer ML; Lenze F; Dziewas R; Warnecke T
    Mov Disord Clin Pract; 2018; 5(4):406-412. PubMed ID: 30363410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CSF α-synuclein and UCH-L1 levels in Parkinson's disease and atypical parkinsonian disorders.
    Mondello S; Constantinescu R; Zetterberg H; Andreasson U; Holmberg B; Jeromin A
    Parkinsonism Relat Disord; 2014 Apr; 20(4):382-7. PubMed ID: 24507721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tau protein quantification in skin biopsies differentiates tauopathies from alpha-synucleinopathies.
    Vacchi E; Lazzarini E; Pinton S; Chiaro G; Disanto G; Marchi F; Robert T; Staedler C; Galati S; Gobbi C; Barile L; Kaelin-Lang A; Melli G
    Brain; 2022 Aug; 145(8):2755-2768. PubMed ID: 35485527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation.
    Tong J; Wong H; Guttman M; Ang LC; Forno LS; Shimadzu M; Rajput AH; Muenter MD; Kish SJ; Hornykiewicz O; Furukawa Y
    Brain; 2010 Jan; 133(Pt 1):172-88. PubMed ID: 19903734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerebrospinal Fluid Levels of 5-Hydroxyindoleacetic Acid in Parkinson's Disease and Atypical Parkinsonian Syndromes.
    Kaiserova M; Chudackova M; Prikrylova Vranova H; Mensikova K; Kastelikova A; Stejskal D; Kanovsky P
    Neurodegener Dis; 2021; 21(1-2):30-35. PubMed ID: 34695830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and validation of the automated imaging differentiation in parkinsonism (AID-P): a multicentre machine learning study.
    Archer DB; Bricker JT; Chu WT; Burciu RG; McCracken JL; Lai S; Coombes SA; Fang R; Barmpoutis A; Corcos DM; Kurani AS; Mitchell T; Black ML; Herschel E; Simuni T; Parrish TB; Comella C; Xie T; Seppi K; Bohnen NI; Müller ML; Albin RL; Krismer F; Du G; Lewis MM; Huang X; Li H; Pasternak O; McFarland NR; Okun MS; Vaillancourt DE
    Lancet Digit Health; 2019 Sep; 1(5):e222-e231. PubMed ID: 33323270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Esophageal dysfunction in different stages of Parkinson's disease.
    Suttrup I; Suttrup J; Suntrup-Krueger S; Siemer ML; Bauer J; Hamacher C; Oelenberg S; Domagk D; Dziewas R; Warnecke T
    Neurogastroenterol Motil; 2017 Jan; 29(1):. PubMed ID: 27477636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy Targeting Neurodegenerative Proteinopathies: α-Synucleinopathies and Tauopathies.
    Shin J; Kim HJ; Jeon B
    J Mov Disord; 2020 Jan; 13(1):11-19. PubMed ID: 31847513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Free-water imaging in Parkinson's disease and atypical parkinsonism.
    Planetta PJ; Ofori E; Pasternak O; Burciu RG; Shukla P; DeSimone JC; Okun MS; McFarland NR; Vaillancourt DE
    Brain; 2016 Feb; 139(Pt 2):495-508. PubMed ID: 26705348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lower urinary tract dysfunction in Parkinsonian syndromes.
    Vichayanrat E; Hentzen C; Batla A; Simeoni S; Iodice V; Panicker JN
    Neurol Sci; 2021 Oct; 42(10):4045-4054. PubMed ID: 34318363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diffusion tensor imaging differentiates vascular parkinsonism from parkinsonian syndromes of degenerative origin in elderly subjects.
    Deverdun J; Menjot de Champfleur S; Cabello-Aguilar S; Maury F; Molino F; Charif M; Leboucq N; Ayrignac X; Labauge P; Bonafe A; Castelnovo G; Le Bars E; Geny C; Menjot de Champfleur N
    Eur J Radiol; 2014 Nov; 83(11):2074-9. PubMed ID: 25154005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of α-Synuclein in L1CAM-Immunocaptured Exosomes as a Biomarker for the Stratification of Parkinsonian Syndromes.
    Jiang C; Hopfner F; Berg D; Hu MT; Pilotto A; Borroni B; Davis JJ; Tofaris GK
    Mov Disord; 2021 Nov; 36(11):2663-2669. PubMed ID: 33826157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroimaging Advances in Parkinson's Disease and Atypical Parkinsonian Syndromes.
    Saeed U; Lang AE; Masellis M
    Front Neurol; 2020; 11():572976. PubMed ID: 33178113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-of-illness in multiple system atrophy and progressive supranuclear palsy.
    Winter Y; Stamelou M; Cabanel N; Sixel-Döring F; Eggert K; Höglinger GU; Herting B; Klockgether T; Reichmann H; Oertel WH; Dodel R; Spottke AE
    J Neurol; 2011 Oct; 258(10):1827-34. PubMed ID: 21479850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The glial marker YKL-40 is decreased in synucleinopathies.
    Olsson B; Constantinescu R; Holmberg B; Andreasen N; Blennow K; Zetterberg H
    Mov Disord; 2013 Nov; 28(13):1882-5. PubMed ID: 23847144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progressive supranuclear palsy phenotype mimicking synucleinopathies.
    Menšíková K; Matěj R; Tučková L; Rusina R; Ehrmann J; Kaňovský P
    J Neurol Sci; 2013 Jun; 329(1-2):34-7. PubMed ID: 23590894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Positron emission tomography imaging of tau pathology in progressive supranuclear palsy.
    Coakeley S; Cho SS; Koshimori Y; Rusjan P; Harris M; Ghadery C; Kim J; Lang AE; Wilson A; Houle S; Strafella AP
    J Cereb Blood Flow Metab; 2017 Sep; 37(9):3150-3160. PubMed ID: 28155586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel Therapies for Parkinsonian Syndromes-Recent Progress and Future Perspectives.
    Przewodowska D; Marzec W; Madetko N
    Front Mol Neurosci; 2021; 14():720220. PubMed ID: 34512258
    [No Abstract]   [Full Text] [Related]  

  • 19. Iron deposition in Parkinsonisms: A Quantitative Susceptibility Mapping study in the deep grey matter.
    Fedeli MP; Contarino VE; Siggillino S; Samoylova N; Calloni S; Melazzini L; Conte G; Sacilotto G; Pezzoli G; Triulzi FM; Scola E
    Eur J Radiol; 2020 Dec; 133():109394. PubMed ID: 33190103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of the movement disorder society criteria for the diagnosis of 4-repeat tauopathies.
    Respondek G; Grimm MJ; Piot I; Arzberger T; Compta Y; Englund E; Ferguson LW; Gelpi E; Roeber S; Giese A; Grossman M; Irwin DJ; Meissner WG; Nilsson C; Pantelyat A; Rajput A; van Swieten JC; Troakes C; Höglinger GU;
    Mov Disord; 2020 Jan; 35(1):171-176. PubMed ID: 31571273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.